In-house roundup: US TERM Act is "blunt instrument"; SPC waiver prep begins; China patent amendment not enough; Insurtech filing surge to continue

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

In-house roundup: US TERM Act is "blunt instrument"; SPC waiver prep begins; China patent amendment not enough; Insurtech filing surge to continue

Money

Managing IP rounds up the latest news and analysis from in-house counsel in patent-focused businesses

Money

US TERM bill is “blunt instrument” that would be disastrous say drug innovators

Proposed legislation in the US House of Representatives seeks to limit patent term extension for pharmaceutical products in a way that pharma innovators say would stifle innovation and not solve potential drug pricing problems. Read More... 

SPC waiver: drug companies and patent offices start preparations

With the EU SPC Manufacturing Waiver due to come into force next week, innovators, generics and patent offices say that they are looking at which products might be affected and whether to charge notification fees. Read more... 

Foreign businesses worried China’s Patent Law changes are too modest

In-house counsel say they would have preferred to have seen more robust changes in the fourth amendment to China’s Patent Law as well as better predictability of rulings. Read more... 

Insurtech patent filings will grow as innovation becomes more important say insurance companies

With insurtech patents increasing by 40% in 2017, in-house counsel at Allstate, The Hartford and elsewhere say filings will continue to go up as they seek to become more customer-centric organisations. Read more... 



more from across site and SHARED ros bottom lb

More from across our site

Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Yonatan Drori, attorney at Drori-Stav IP in Israel, explains why foreign counsel must treat Israel’s patent disclosure requirements as an ongoing obligation, rather than a one-off formality
From Japan to Southeast Asia, domestic and regional firms picked up some of the biggest prizes, while key foreign players maintained momentum
Earlier this month, Managing IP had exclusively reported that the French arm of Taylor Wessing was minded to pull out of the deal
Our latest podcast examines how Weil’s IP practice evolved, where its practitioners could (and will) go next, and which firms and markets stand to benefit from the redistribution of talent
Former Latham partner Chris Henry and transactions lawyer Liza Cotter are heading to the firm as Weil’s IP practice starts to disperse
Rival IP teams return to court for a closely watched appeal over AI and copyright, but observers hoping for answers to some of the technology’s biggest legal questions may be left disappointed
Eight years after its launch, members of the Australian patent firm’s Singapore office explain its growth strategy over the past year
Gift this article